Information Provided By:
Fly News Breaks for May 31, 2016
RARE
May 31, 2016 | 07:29 EDT
After meeting with an expert on Glut 1 DS, Stifel thinks that the study of Ultragenyx's trihep as a treatment for P2 seizures in 2H16 will yield positive results. Additionally, the firm now believes that the Glut 1 DS seizure population is larger than it previously thought, while Ultragenyx's drug may achieve a 100% penetration rate in the target population, versus its previous model of 70%. Stifel keeps a $125 price target and Buy rating on the shares.
News For RARE From the Last 2 Days
There are no results for your query RARE